Diagnosis and Management of Graves' Disease
Literature Review
DOI:
https://doi.org/10.55175/cdk.v52i4.1510Keywords:
Hyperthyroid, Graves’ disease, thyroidAbstract
Graves’ disease is the primary cause (60%-80%) of hyperthyroidism. The risk factors include genetic, environmental, and immunological aspects, with a higher prevalence in women. The diagnosis is based on medical history and physical examination, supported by Wayne index, as well as appropriate diagnostic tests including thyroid function tests, antibody testing, thyroid scan, or color-doppler ultrasonography. Treatment options include anti-thyroid medication, radioactive iodine treatment (RAI), and surgery. Complications include Graves’ ophthalmopathy, thyroid dermopathy, cardiovascular effects, and thyroid crisis. The prognosis depends on the likelihood of remission and relapse, with remission being more common in adults than in children.
Downloads
References
Pokhrel B, Bhusal K. Graves disease. StatPearls Publishing; 2024.
Loscalzo J, Fauci A, Kasper D, Hauser S, Longo D, Jameson JL. Harrison's principles of internal medicine. 21st Ed. New York: McGraw Hill; 2022.
Kusrini I, Kumorowulan S. Nilai diagnostik indeks Wayne dan indeks Newcastle untuk penapisan kasus hipertiroid. Balai Penelitian dan Pengembangan GAKI, Kemenkes RI; 2010.
Gardner DG, Shoback DM, Greenspan FS. Greenspan's basic & clinical endocrinology. New York (NY): McGraw-Hill Ed; 2018.
Ferrari SM, Fallahi P, Ruffilli I, Elia G, Ragusa F, Benvenga S, et al. The association of other autoimmune diseases in patients with Graves’ disease (with or without ophthalmopathy): review of the literature and report of a large series. Autoimmun Rev. 2019;18(3):287–92. DOI: 10.1016/j.autrev.2018.10.001.
Rotondi M, Virili C, Pinto S, Coperchini F, Croce L, Brusca N, et al. The clinical phenotype of Graves’ disease occurring as an isolated condition or in association with other autoimmune diseases. J Endocrinol Investig. 2020;43(2):157–62. DOI: 10.1007/s40618-019-01094-7.
Smith TJ, Hegedus L. Graves' disease. N Engl J Med. 2016;375(16):1552-65. DOI: 10.1056/NEJMra1510030.
Antonelli A, Ferrari SM, Ragusa F, Elia G, Paparo SR, Ruffilli I, et al. Graves’ disease: Epidemiology, genetic and environmental risk factors and viruses. Best Pract Res Clin Endocrinol Metab. 2020;34:101387. DOI: 10.1016/j.beem.2020.101387.
Indonesian Society of Endocrinology Task Force on Thyroid Diseases. Indonesian clinical practice guidelines for hyperthyroidism. J ASEAN Fed Endocrine Soc. 2012;27(1):34-9.
Subekti I, Pramono LA. Current diagnosis and management of Graves' disease. Acta Med Indonesia 2018;50(2):177-82.
Kahaly GJ, Bartalena L, Hegedus L, Leenhardt L, Poppe K, Pearce SH. 2018 European Thyroid Association guideline for the management of Graves’ hyperthyroidism. Eur Thyroid J. 2018;7(4):167–86. DOI: 10.1159/000490384.
Davies TF, Andersen S, Latif R, Nagayama Y, Barbesino G, Brito M, et al. Graves’ disease. Nat Rev Dis Primers 2020;6(1):52.
Simon M, Rigou A, Le Moal J, Zeghnoun A, Le Tertre A, De Crouy-Chanel P, et al. Epidemiology of childhood hyperthyroidism in france: A nationwide population-based study. J Clin Endocrinol Metab; 2018;103:2980–7. DOI: 10.1210/jc.2018-00273.
Metwalley KA, Farghaly HS. Graves' disease in children: An update. Clin Med Insights Endocrinol Diabetes 2023;16:11795514221150615. DOI: 10.1177/11795514221150615.
Burch HB, Cooper DS. Management of Graves disease: A review. JAMA 2015;314:2544-54. DOI: 10.1001/jama.2015.16535.
Metwalley KA, Farghaly HS, Raafat DM, Ismail AM, Saied GM. Soluble CD40 ligand levels in children with newly diagnosed Graves’ disease. J Clin Res Pediatr Endocrinol. 2020;12:197-201. DOI: 10.4274/jcrpe.galenos.2019.2019.0108.
Mooij CF, Cheetham TD, Verburg FA, Eckstein A, Pearce SH, Leger J, et al. 2022 European Thyroid Association guideline for the management of pediatric Graves’ disease. Eur Thyroid J. 2022;11:e210073. DOI: 10.1530/ETJ-21-0073.
Committee on Pharmaceutical Affairs, Japanese Society for Pediatric Endocrinology, and the Pediatric Thyroid Disease Committee, Japan Thyroid Association (Taskforce for the Revision of the Guidelines for the Treatment of Childhood-Onset Graves’ Disease); Minamitani K, Sato H, Ohye H, Harada S, Arisaka O. Guidelines for the treatment of childhood-onset Graves' disease in Japan, 2016. Clin Pediatr Endocrinol. 2017;26(2):29-62. DOI: 10.1297/cpe.26.29.
Reddy V, Taha W, Kundumadam S, Khan M. Atrial fibrillation and hyperthyroidism: A literature review. Indian Heart J. 2017;69(4):545-50. DOI: 10.1016/j.ihj.2017.07.004.
Pokhrel B, Aiman W, Bhusal K. Thyroid storm. StatPearls Publishing; 2024.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Eric Ricardo Yonatan
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
